Humacyte Inc (HUMA) Stock: Evaluating the Annual Growth

In the past week, HUMA stock has gone down by -1.30%, with a monthly decline of -14.16% and a quarterly surge of 4.84%. The volatility ratio for the week is 4.50%, and the volatility levels for the last 30 days are 6.71% for Humacyte Inc The simple moving average for the last 20 days is -7.37% for HUMA’s stock, with a simple moving average of -1.35% for the last 200 days.

Is It Worth Investing in Humacyte Inc (NASDAQ: HUMA) Right Now?

The 36-month beta value for HUMA is at 1.45. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for HUMA is 86.14M, and currently, shorts hold a 4.39% of that float. The average trading volume for HUMA on April 04, 2024 was 950.93K shares.

HUMA) stock’s latest price update

The stock of Humacyte Inc (NASDAQ: HUMA) has increased by 2.02 when compared to last closing price of 2.97.Despite this, the company has seen a loss of -1.30% in its stock price over the last five trading days. InvestorPlace reported 2024-03-22 that Humacyte (NASDAQ: HUMA ) just reported results for the fourth quarter of 2023. Humacyte reported earnings per share of -24 cents.

Analysts’ Opinion of HUMA

Many brokerage firms have already submitted their reports for HUMA stocks, with H.C. Wainwright repeating the rating for HUMA by listing it as a “Buy.” The predicted price for HUMA in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 11, 2023 of the previous year 2023.

Piper Sandler, on the other hand, stated in their research note that they expect to see HUMA reach a price target of $3.50, previously predicting the price at $2.75. The rating they have provided for HUMA stocks is “Neutral” according to the report published on August 14th, 2023.

Cantor Fitzgerald gave a rating of “Overweight” to HUMA, setting the target price at $6 in the report published on June 22nd of the previous year.

HUMA Trading at -13.99% from the 50-Day Moving Average

After a stumble in the market that brought HUMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.89% of loss for the given period.

Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 4.50%, as shares sank -12.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.45% upper at present.

During the last 5 trading sessions, HUMA fell by -1.30%, which changed the moving average for the period of 200-days by -9.55% in comparison to the 20-day moving average, which settled at $3.25. In addition, Humacyte Inc saw 6.69% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at HUMA starting from Dougan Brady W, who sale 2,000,000 shares at the price of $2.78 back on Sep 14 ’23. After this action, Dougan Brady W now owns 6,191,140 shares of Humacyte Inc, valued at $5,560,000 using the latest closing price.

Niklason Laura E, the President, CEO and Director of Humacyte Inc, sale 2,000,000 shares at $2.78 during a trade that took place back on Sep 14 ’23, which means that Niklason Laura E is holding 6,191,140 shares at $5,560,000 based on the most recent closing price.

Stock Fundamentals for HUMA

The total capital return value is set at -0.91. Equity return is now at value -169.81, with -66.63 for asset returns.

Based on Humacyte Inc (HUMA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -1.78. The debt to equity ratio resting at 3.04. The interest coverage ratio of the stock is -15.16.

Currently, EBITDA for the company is -92.33 million with net debt to EBITDA at 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.52.


In conclusion, Humacyte Inc (HUMA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts